Skip to content

Remedy Robotics lands $62M to push FDA submission for AI telesurgery

·StartupReader editorial desk· 2 min readReviewed by our editors
FUNDING. $62M, AI telesurgery system. Stage: Series B.

Remedy Robotics has secured $62 million in Series B funding to advance its AI-powered telesurgical system toward an FDA submission, according to *MassDevice*. The money will help the company hit key development milestones needed to get regulatory approval, putting it in a position to compete in an area where precision, remote operation, and affordability are becoming more important.

This funding follows a recent wave of investment in AI-driven medical hardware. Just this month, Spiko raised $90 million for spacetech infrastructure, while Ultra Robotics pulled in $62 million for warehouse automation—both rounds reflecting broader trends in their respective fields. But Remedy’s focus on endovascular intervention, a minimally invasive heart procedure, makes it different. The company’s tagline—*"AI-powered endovascular intervention for every patient, everywhere"*—suggests a two-part approach: using automation to help with surgeon shortages while making care more available in places where it’s hard to get.

The success of this round will depend on how quickly the company can move through FDA review. Unlike software or cloud-based businesses, medical devices need extensive testing to prove they work safely and effectively. Remedy’s path to approval will likely be expensive and take time. The question is whether the company can show the system’s benefits in trials without running out of money too soon. Ultra Robotics, for example, raised $62 million across two rounds last week, but its warehouse robots face their own set of regulatory and adoption challenges.

What’s clear is that Remedy is betting on a future where AI doesn’t just support surgeons but changes how procedures are done. If the FDA submission goes as planned, it could set a precedent for other startups trying to automate high-stakes medical work. For now, though, the company has limited time—both to spend the funding wisely and to gather the evidence it needs to prove the system works.

Sources: massdevice.com

“Investors are increasingly backing AI-assisted surgical tools as a way to expand expertise and cut costs, but the biggest challenge remains navigating FDA approval.”
— StartupReader
ShareLinkedInXWhatsApp

One of the funding rounds reported in the week of 16–22 November 2026. See every round that week.

Read the original reporting

The outlets below did the original reporting.

Related briefs

This brief was drafted automatically from the sources above and published under our editorial policy. Spotted an error? Tell us.